Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
5.43
+0.07 (1.31%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Atea Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
435.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 351.37M | 302.73M | 622.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| vTv Therapeutics | 36.84M |
| Foghorn Therapeutics | 36.74M |
| X4 Pharmaceuticals | 15.85M |
| Ocugen | 4.58M |
| EyePoint | 2.79M |
| Compass Therapeutics | 850.00K |
| Inhibikase Therapeutics | 1.00 |
AVIR News
- 5 days ago - Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley - TheFly
- 9 days ago - Atea Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 9 days ago - Atea Pharmaceuticals Earnings release: Q2 2026 - Filings
- 9 days ago - Atea Pharmaceuticals Slides: Q2 2026 - Filings
- 9 days ago - Atea Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 10 days ago - Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 - GlobeNewsWire
- 25 days ago - Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints - TheFly